オピオイド誘発性便秘市場：有効成分、薬剤クラス別、投与方法、流通チャネル-2025-2030年の世界予測

オピオイド誘発性便秘市場は、2023年に6,595万米ドルと評価され、2024年には7,010万米ドルに達すると予測され、CAGR 6.69％で成長し、2030年には1億378万米ドルに達すると予測されています。

オピオイド誘発性便秘（OIC）は、疼痛管理のためにオピオイド鎮痛薬を使用している患者によく見られる副作用であり、製薬企業やヘルスケアプロバイダーにとって重要な関心分野となっています。慢性疼痛の増加とそれに伴うオピオイド消費量の増加により、効果的なOIC管理ソリューションの必要性が高まっています。主な用途には、便秘症状の緩和を目的とした処方薬、市販薬、非薬理学的介入が含まれます。エンドユーザーは、病院、在宅ケア環境、専門クリニックなど多岐にわたる。主な成長要因としては、オピオイドの副作用に対する意識の高まり、薬剤製剤の進歩、ヘルスケア支出の増加などが挙げられます。最新のビジネスチャンスは、便秘に影響を及ぼす遺伝的要因や生活習慣的要因を考慮した患者別ソリューションに焦点を当てた個別化医療アプローチにあります。企業は、患者教育に投資し、包括的なOIC管理プログラムを開発することで、こうした機会を活用することができます。しかし、新薬承認のための厳しい規制要件、オピオイドの長期使用に伴うスティグマ、OICと他のタイプの便秘の正確な診断の複雑さなどの課題に直面しています。革新的な研究分野としては、便秘のリスクを最小化または排除する非オピオイド疼痛管理ソリューションの開発や、デジタルヘルスツールを活用して症状を効果的に監視・管理することなどが挙げられます。また、OICにおけるマイクロバイオームの役割を解明し、新たな治療標的を見出すことを目的とした調査も可能です。こうした課題にもかかわらず、OIC治療薬の世界市場は、高齢化と慢性疼痛の罹患率の上昇に伴い拡大が見込まれています。このニッチ分野の治療主は、進化する規制基準に対応し、ヘルスケアプロバイダーとの連携を促進し、最先端の治療オプションを統合した全人的で患者中心のケアモデルの開発を重視することで、市場への浸透を強化することができます。

市場力学：急速に進化するオピオイド誘発性便秘市場の主要市場インサイトを公開

オピオイド誘発性便秘市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 便秘を合併する老年人口の増加
  • 腎臓疾患の有病率の増加
  • 多様な治療法の利用可能性の急増
• 市場抑制要因
  • 厳しい承認プロセスと時間のかかる作業
• 市場機会
  • オピオイドの使用拡大
  • 小売薬局での入手可能性の上昇
• 市場の課題
  • オピオイド耐性と中毒に関する懸念

ポーターの5つの力オピオイド誘発性便秘市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：オピオイド誘発性便秘市場における外部からの影響の把握

外部マクロ環境要因は、オピオイド誘発性便秘市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析オピオイド誘発性便秘市場における競合情勢の把握

オピオイド誘発性便秘市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスオピオイド誘発性便秘市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、オピオイド誘発性便秘市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨オピオイド誘発性便秘市場における成功への道筋を描く

オピオイド誘発性便秘市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 便秘合併症のある高齢者人口の増加
    • 腎臓疾患の増加
    • 多様な治療法の普及
  • 抑制要因
    • 厳格な承認プロセスと時間のかかる
  • 機会
    • オピオイドの使用増加
    • 小売薬局での入手可能性の向上
  • 課題
    • オピオイド耐性と依存症に関する懸念
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 オピオイド誘発性便秘市場有効成分別

• 膨張性下剤、刺激性下剤
• ドキュセートナトリウム
• 軟化剤/潤滑剤下剤
• ルビプロストン
• メチルナルトレキソン臭化物
• ナロキセゴール
• 浸透圧性下剤
• プロスタグランジン/消化管運動促進薬

第7章 オピオイド誘発性便秘市場薬剤クラス別

• 局所作用型塩素チャネル活性化剤（LACCA）
• 非選択的オピオイド拮抗薬
• 末梢性制限性μオピオイド受容体拮抗薬（PAMORA）
• μ-オピオイド拮抗薬

第8章 オピオイド誘発性便秘市場投与方法別

• オーラル
• 非経口

第9章 オピオイド誘発性便秘市場：流通チャネル別

• ドラッグストア
• 病院薬局
• 独立薬局

第10章 南北アメリカのオピオイド誘発性便秘市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のオピオイド誘発性便秘市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのオピオイド誘発性便秘市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AstraZeneca PLC
• Fresenius Kabi AG
• GlaxoSmithKline PLC
• Hikma Pharmaceuticals PLC
• Ironwood Pharmaceuticals, Inc.
• Lantheus
• Mylan by Viatris Inc.
• Pfizer, Inc.
• RedHill Biopharma Inc.
• Salix Pharmaceuticals by Bausch Health Companies Inc.
• Shionogo & Co. Ltd.
• SLA Pharma AG
• Synergy Pharmaceuticals Inc.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. OPIOID INDUCED CONSTIPATION MARKET RESEARCH PROCESS
• FIGURE 2. OPIOID INDUCED CONSTIPATION MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. OPIOID INDUCED CONSTIPATION MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. OPIOID INDUCED CONSTIPATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. OPIOID INDUCED CONSTIPATION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. OPIOID INDUCED CONSTIPATION MARKET DYNAMICS
• TABLE 7. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY BULK CATHARTICS, STIMULANT CATHARTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DOCUSATE SODIUM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY EMOLLIENT/LUBRICANT CATHARTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LUBIPROSTONE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY METHYLNALTREXONE BROMIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALOXEGOL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY OSMOTIC LAXATIVES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PROSTAGLANDINS/PROKINETIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LOCALLY ACTING CHLORIDE CHANNEL ACTIVATOR (LACCA), BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NON-SELECTIVE OPIOID ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY-RESTRICTED M-OPIOID RECEPTOR ANTAGONIST (PAMORA), BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY M-OPIOID ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG STORE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 42. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 43. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 44. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 60. AUSTRALIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 61. AUSTRALIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. AUSTRALIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 63. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 64. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 65. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 66. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. INDIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 68. INDIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 69. INDIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. INDIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 72. INDONESIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 73. INDONESIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. INDONESIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 76. JAPAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 77. JAPAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. JAPAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 80. MALAYSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 81. MALAYSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 82. MALAYSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 84. PHILIPPINES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 85. PHILIPPINES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. PHILIPPINES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 88. SINGAPORE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 89. SINGAPORE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 90. SINGAPORE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH KOREA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 93. SOUTH KOREA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. SOUTH KOREA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 96. TAIWAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 97. TAIWAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. TAIWAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 100. THAILAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 101. THAILAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 102. THAILAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 104. VIETNAM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 105. VIETNAM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 106. VIETNAM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 110. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 111. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 113. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 114. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 115. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 117. EGYPT OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 118. EGYPT OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 119. EGYPT OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 121. FINLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 122. FINLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. FINLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 125. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 126. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 127. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 129. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 130. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 131. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 133. ISRAEL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 134. ISRAEL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 135. ISRAEL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 136. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 137. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 138. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 141. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 142. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 145. NIGERIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 146. NIGERIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 147. NIGERIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 149. NORWAY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 150. NORWAY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 151. NORWAY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 152. POLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 153. POLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 154. POLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 155. POLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 156. QATAR OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 157. QATAR OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 158. QATAR OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 159. QATAR OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 161. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 162. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 163. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 165. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 166. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 167. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 171. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 173. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 174. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 175. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 177. SWEDEN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 178. SWEDEN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 179. SWEDEN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 181. SWITZERLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 182. SWITZERLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 183. SWITZERLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 185. TURKEY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 186. TURKEY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 187. TURKEY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 189. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 190. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 191. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
• TABLE 193. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 194. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 195. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 196. OPIOID INDUCED CONSTIPATION MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 197. OPIOID INDUCED CONSTIPATION MARKET, FPNV POSITIONING MATRIX, 2023

The Opioid Induced Constipation Market was valued at USD 65.95 million in 2023, expected to reach USD 70.10 million in 2024, and is projected to grow at a CAGR of 6.69%, to USD 103.78 million by 2030.

Opioid Induced Constipation (OIC) is a common side effect among patients using opioid analgesics for pain management, posing a significant area of interest for pharmaceutical companies and healthcare providers. The increasing prevalence of chronic pain and the subsequent rise in opioid consumption drive the necessity for effective OIC management solutions. Key applications include prescription medications, over-the-counter remedies, and non-pharmacological interventions aimed at alleviating constipation symptoms. The end-users span across hospitals, home care settings, and specialty clinics. Key growth influencers include the growing awareness surrounding opioid side effects, advancements in drug formulations, and increased healthcare spending. The latest opportunities lie in personalized medicine approaches, focusing on patient-specific solutions that consider genetic and lifestyle factors influencing constipation. Companies can capitalize on these opportunities by investing in patient education and developing comprehensive OIC management programs. However, market growth faces challenges such as stringent regulatory requirements for new drug approvals, the stigma associated with long-term opioid use, and the complexity of accurately diagnosing OIC versus other types of constipation. Innovation areas ripe for exploration include developing non-opioid pain management solutions that minimize or eliminate the risk of constipation, as well as leveraging digital health tools to monitor and manage symptoms effectively. Research can also be targeted towards understanding the microbiome's role in OIC, offering insights into novel therapeutic targets. Despite these challenges, the global market for OIC therapies is expected to grow as the aging population and incidence of chronic pain increase. Businesses within this niche can enhance market penetration by aligning with evolving regulatory standards, fostering collaborations with healthcare providers, and emphasizing the development of holistic and patient-centric care models that integrate cutting-edge treatment options.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Opioid Induced Constipation Market

The Opioid Induced Constipation Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising geriatric population with constipation complications
  • Growing prevalence of kidney disorders
  • Surging availability of diversified treatments
• Market Restraints
  • Stringent approval process and time-consuming
• Market Opportunities
  • Proliferating use of opioids
  • Rise in availability in retail pharmacies
• Market Challenges
  • Concern regarding opioid tolerance and addiction

Porter's Five Forces: A Strategic Tool for Navigating the Opioid Induced Constipation Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Opioid Induced Constipation Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Opioid Induced Constipation Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Opioid Induced Constipation Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Opioid Induced Constipation Market

A detailed market share analysis in the Opioid Induced Constipation Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Opioid Induced Constipation Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Opioid Induced Constipation Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Opioid Induced Constipation Market

A strategic analysis of the Opioid Induced Constipation Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Opioid Induced Constipation Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Fresenius Kabi AG, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Ironwood Pharmaceuticals, Inc., Lantheus, Mylan by Viatris Inc., Pfizer, Inc., RedHill Biopharma Inc., Salix Pharmaceuticals by Bausch Health Companies Inc., Shionogo & Co. Ltd., SLA Pharma AG, Synergy Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Opioid Induced Constipation Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Active Ingredients, market is studied across Bulk Cathartics, Stimulant Cathartics, Docusate Sodium, Emollient/Lubricant Cathartics, Lubiprostone, Methylnaltrexone Bromide, Naloxegol, Osmotic laxatives, and Prostaglandins/Prokinetic Drugs.
• Based on Drug Class, market is studied across Locally Acting Chloride Channel Activator (LACCA), Non-Selective Opioid Antagonist, Peripherally-Restricted μ-Opioid Receptor Antagonist (PAMORA), and μ-Opioid Antagonist.
• Based on Mode of Administration, market is studied across Oral and Parenteral.
• Based on Distribution Channel, market is studied across Drug Store, Hospital Pharmacies, and Independent Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising geriatric population with constipation complications
    • 5.1.1.2. Growing prevalence of kidney disorders
    • 5.1.1.3. Surging availability of diversified treatments
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent approval process and time-consuming
  • 5.1.3. Opportunities
    • 5.1.3.1. Proliferating use of opioids
    • 5.1.3.2. Rise in availability in retail pharmacies
  • 5.1.4. Challenges
    • 5.1.4.1. Concern regarding opioid tolerance and addiction
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Opioid Induced Constipation Market, by Active Ingredients

• 6.1. Introduction
• 6.2. Bulk Cathartics, Stimulant Cathartics
• 6.3. Docusate Sodium
• 6.4. Emollient/Lubricant Cathartics
• 6.5. Lubiprostone
• 6.6. Methylnaltrexone Bromide
• 6.7. Naloxegol
• 6.8. Osmotic laxatives
• 6.9. Prostaglandins/Prokinetic Drugs

7. Opioid Induced Constipation Market, by Drug Class

• 7.1. Introduction
• 7.2. Locally Acting Chloride Channel Activator (LACCA)
• 7.3. Non-Selective Opioid Antagonist
• 7.4. Peripherally-Restricted μ-Opioid Receptor Antagonist (PAMORA)
• 7.5. μ-Opioid Antagonist

8. Opioid Induced Constipation Market, by Mode of Administration

• 8.1. Introduction
• 8.2. Oral
• 8.3. Parenteral

9. Opioid Induced Constipation Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Drug Store
• 9.3. Hospital Pharmacies
• 9.4. Independent Pharmacies

10. Americas Opioid Induced Constipation Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Opioid Induced Constipation Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Opioid Induced Constipation Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AstraZeneca PLC
• 2. Fresenius Kabi AG
• 3. GlaxoSmithKline PLC
• 4. Hikma Pharmaceuticals PLC
• 5. Ironwood Pharmaceuticals, Inc.
• 6. Lantheus
• 7. Mylan by Viatris Inc.
• 8. Pfizer, Inc.
• 9. RedHill Biopharma Inc.
• 10. Salix Pharmaceuticals by Bausch Health Companies Inc.
• 11. Shionogo & Co. Ltd.
• 12. SLA Pharma AG
• 13. Synergy Pharmaceuticals Inc.
• 14. Takeda Pharmaceutical Company Limited
• 15. Teva Pharmaceutical Industries Ltd.